Summary of the FP7 Health projects written by Mrs Martine Peers

European Office Research Support Unit

Dear colleagues,

Please see below an update about the first 2 Health calls, together with a list of themes expected to be included in the 3rd Health call expected to be published in July with a deadline in October 2008.  This was circulated by the Health NCP (http://www.fp7uk.co.uk/ http://www.fp7uk.co.uk/ http://www.fp7uk.co.uk/ ), Tel 0870600 6080

First call: FP7-HEALTH-2007-A.

Are budget reductions a thing of the past? Not quite. With respect to the budget figures the NCP has access to for first call proposals, the majority of those funded will receive the EC contribution asked for. In a limited number of cases the EC contribution was actually increased during negotiation. In those where the budget was reduced, in 9/10 cases, the reduction was by no more than 4%.

Second call: FP7-Health-2007-B.

Independent Observers Report.

This is available on CORDIS.  The report covers the role of the Independent Observers in the evaluation process, selection and briefing of experts, feedback on the evaluation process itself and recommendations for the EC to consider for future calls. Download the full report from the Health home page on CORDIS.

Third call - due to open July 2008.

In February, the EC circulated their research priorities for the third call to the Programme Committee (PC). Following a period of consultation, the result was the first draft of the workprogramme which was made available to the PC this month. Not all activities in the workprogramme will open in the third call. 

Activities closed for the third call.

1)    Suitability, Safety and Efficacy of Medicines.

2)    Human Development and Ageing

3)    Cancer

Suitability, Safety and Efficacy, with the exception of Alternative Testing Strategies, will be addressed through the workprogramme of the Innovative Medicines Initiative, not through the Health workprogramme. It is intended that the Human Development activity and Cancer activity be addressed in the fourth call, 2009.

For an idea of some of the research priorities under consideration, please continue to read.

Activity 1: Biotechnology, generic tools and technologies

1.1 *High Throughput research.

1.2 Detection, diagnosis and monitoring.

1.4 Innovative therapeutic approaches and interventions (regenerative medicine).

Activity 2: Translating research for human health.

2.1.1 *Large-scale data gathering.

2.1.2 *Systems Biology.

2.2.1 Brain and brain-related diseases (synaptopathies, schizophrenia, neurological pain).

2.3.1 Antimicrobial drug resistance.

2.3.2 HIV/AIDS, Malaria and TB (vaccines and microbicides).

2.3.3 Emerging epidemics (prevention of 'flu transmission).

2.3.4 Neglected infectious diseases (all topics in this activity are labeled Specific International Cooperation Activity, see below).

2.3.4 Cardiovascular disease (including research into cardiac arrhythmias and cardiomyopathy).

2.4.3 Diabetes and obesity (including pregnancy diabetes and novel immunotherapies for type 1 diabetes).

2.4.4 Rare diseases (rare neurological conditions, orphan drugs).

2.4.5: Other chronic diseases (non-alcoholic fatty liver disease, chronic kidney disease).

Activity 3: Optimising the delivery of healthcare.

3.1 Translating the results of clinical practice (including prevention of healthcare acquired infections, complementary and alternative medicine).

3.2 Quality, efficiency and solidarity of healthcare systems (including organisation of dementia care, access to comparable health care data).

3.3 Enhanced health promotion and disease prevention (including adolescent ental health and substance abuse).

Activity 4: Other actions across the theme.

4.1 Coordination and Support Actions across the theme (including dssemination and technology transfer of results from Health and Life

Sciences for Health projects)

4.2 Responding to EU policy needs (including adapting off-patent medicines for paediatric use, drug safety research)

4.3 Specific International Cooperation Actions (SICA)

4.3.1 Neglected Infectious diseases (including helminth infections, neglected bacterial infections).

4.3.2 International public health and health systems (including improving reproductive health).

4.3.3 Coordinated topics with Russia.

Activities marked thus* will pilot a two-stage submission procedure. The

deadline for the first stage will be in October. Second-stage deadline to be

determined.  All other activities will use a one-stage submission procedure

for a deadline in November, date to be determined.  If you wish to discuss

the third call, please contact the Health NCP.

Innovative Medicines Initiative.

The IMI is due to open its first call for proposals in April. A major

dissemination event is due to held in Brussels on the 30th April which "will

provide potential stakeholders with full details of the scientific

priorities of the IMI. Participants will get initial guidance on the

application procedures for consortia considering making applications for

funding under the first IMI Call for proposals" Full details will be made

available on the IMI website at the end of March:

http://www.imi-europe.org/DetailView.aspx?id=59&source=event

For details about the IMI Call and Evaluation Process, with proposed timelines for submission and evaluation, see the presentation dated 17thMarch 2008, here:

http://www.imi-europe.org/Publications.aspx?viewCategory=Overviewx20Presentations 

http://www.imi-europe.org/Publications.aspx?viewCategory=Overviewx20Presentations

________________________________

3, Cavendish Road

Tel:  0113 343 4300

Fax:  0113 343 3906

E-mail:  This e-mail address is being protected from spam bots, you need JavaScript enabled to view it